CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics. The Post-Transplant Diagnostics segment develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell free DNA test initially used for kidney transplant patients. The Pre-Transplant Diagnostics segment develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HAL) alleles based on sequence-specific primer technology; Olerup QTYPE, a test kit for sequence based HLA typing; Olerup SBT, a test kit for sequence based HLA typing; and XM-ONE, a test that identifies a patient's antigens against HLA Class I or Class II, as well as antibodies against a donor's endothelium. This segment offers its products directly to customers, as well as through third-party distributors. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone415-287-2300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$48.32 million
Profitability
Miscellaneous
Employees179
OptionableOptionable
CareDx (NASDAQ:CDNA) Frequently Asked Questions
What is CareDx's stock symbol?
CareDx trades on the NASDAQ under the ticker symbol "CDNA."
How were CareDx's earnings last quarter?
CareDx Inc (NASDAQ:CDNA) issued its earnings results on Thursday, November, 8th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.42. The company had revenue of $21.18 million for the quarter, compared to analyst estimates of $18.47 million. CareDx had a negative return on equity of 125.24% and a negative net margin of 113.89%. View CareDx's Earnings History.
When is CareDx's next earnings date?
What guidance has CareDx issued on next quarter's earnings?
CareDx issued an update on its FY 2018 earnings guidance on Thursday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $74-75 million, compared to the consensus revenue estimate of $69 million.
What price target have analysts set for CDNA?
4 Wall Street analysts have issued twelve-month price objectives for CareDx's shares. Their forecasts range from $27.00 to $42.00. On average, they anticipate CareDx's share price to reach $34.75 in the next year. This suggests a possible upside of 41.1% from the stock's current price. View Analyst Price Targets for CareDx.
What is the consensus analysts' recommendation for CareDx?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CareDx.
What are Wall Street analysts saying about CareDx stock?
Here are some recent quotes from research analysts about CareDx stock:
- 1. According to Zacks Investment Research, "CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. " (1/8/2019)
- 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $1,123M, which includes a discounted cash flow analysis based asset value for pre- and post-transplant tests, using a 15% discount rate and 2% terminal growth rate, and assuming 41.5M shares outstanding at the end of 2019." (12/21/2018)
Has CareDx been receiving favorable news coverage?
News articles about CDNA stock have trended somewhat negative on Friday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. CareDx earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of CareDx's key competitors?
Some companies that are related to CareDx include Guardant Health (GH), Genomic Health (GHDX), InVitae (NVTA), Natera (NTRA), Veracyte (VCYT), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Psychemedics (PMD), Fulgent Genetics (FLGT), PotNetwork (POTN), First Choice Healthcare Solutions (FCHS), OpGen (OPGN) and CBA Florida (CBAI).
Who are CareDx's key executives?
CareDx's management team includes the folowing people:
- Dr. Peter Maag, CEO & Director (Age 52)
- Mr. Michael Bell, Chief Financial Officer (Age 50)
- Dr. James P. Yee, Chief Medical Officer (Age 70)
- Dr. Reginald Seeto, Pres & Chief Bus. Officer (Age 47)
- Dr. Amy P. Abernethy, Chief Medical Officer, Chief Scientific Officer, Sr. VP of Oncology & Director (Age 50)
Who are CareDx's major shareholders?
CareDx's stock is owned by a number of of institutional and retail investors. Top institutional investors include Gagnon Securities LLC (3.41%), Peregrine Capital Management LLC (1.45%), Gagnon Advisors LLC (1.28%) and Meeder Asset Management Inc. (0.01%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Mitchell J Nelles, Neil Gagnon, Peter Maag and Sasha King. View Institutional Ownership Trends for CareDx.
Which major investors are selling CareDx stock?
CDNA stock was sold by a variety of institutional investors in the last quarter, including Gagnon Advisors LLC, Gagnon Securities LLC and Peregrine Capital Management LLC. Company insiders that have sold CareDx company stock in the last year include Michael Brian Bell, Mitchell J Nelles, Neil Gagnon, Peter Maag and Sasha King. View Insider Buying and Selling for CareDx.
Which major investors are buying CareDx stock?
CDNA stock was acquired by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought CareDx stock in the last two years include Michael Brian Bell, Neil Gagnon and Peter Maag. View Insider Buying and Selling for CareDx.
How do I buy shares of CareDx?
Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CareDx's stock price today?
One share of CDNA stock can currently be purchased for approximately $24.62.
How big of a company is CareDx?
CareDx has a market capitalization of $925.47 million and generates $48.32 million in revenue each year. The company earns $-55,460,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. CareDx employs 179 workers across the globe.
What is CareDx's official website?
How can I contact CareDx?
CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]
MarketBeat Community Rating for CareDx (NASDAQ CDNA)
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe CDNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
